MRUS Live signals | Maximize Profits with Getagraph.com

BUY 101027 min ago

@ $42.61

Issued: 14 Feb 2024 @ 14:47

Return: -1.50%

Previous signal: Feb 13 - 15:34

Previous signal: Sell

Return: 1.44 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	737 700
Average Volume	576 833
Market Cap	2.43B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.830 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.99
ATR14	$0.0650 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-19	Shuman Harry	Sell	115	Common Shares
2023-12-15	Silverman Peter B.	Buy	1 286	Common Shares
2023-12-15	Silverman Peter B.	Buy	21 100	Common Shares
2023-12-15	Silverman Peter B.	Sell	21 100	Share Option (right to buy)
2023-12-15	Silverman Peter B.	Sell	22 386	Common Shares

INSIDER POWER
69.37
Last 99 transactions
Buy: 2 523 001 \| Sell: 3 636 553

Volume Correlation

Long: 0.18 (neutral)

Short: 0.83 (strong)

Signal:(71.246) Same movement expected

Merus NV Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Merus NV Correlation - Currency/Commodity

-0.63
( weak negative )

-0.38
( neutral )

0.00
( neutral )

-0.50
( neutral )

0.56
( weak )

0.57
( weak )

Merus NV Financials

Annual	2023
Revenue:	$43.95M
Gross Profit:	$-83.46M (-189.91 %)
EPS:	$-3.00

Q4	2023
Revenue:	$8.94M
Gross Profit:	$8.94M (100.00 %)
EPS:	$-1.040

Q3	2023
Revenue:	$11.03M
Gross Profit:	$-23.79M (-215.59 %)
EPS:	$-0.430

Q2	2023
Revenue:	$10.48M
Gross Profit:	$-15.46M (-147.54 %)
EPS:	$-0.660

Financial Reports:

No articles found.

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.